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Objectives: In 2018, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) intro-
duced an intermediate breakpoint for ceftaroline against Staphylococcus aureus. The objective of this
study was to compare data on resistance to ceftaroline among methicillin-resistant S. aureus (MRSA)
isolates using versions 7.1 (March 2017) and 8.0 (January 2018) of the EUCAST breakpoints.
Methods: Participating centers were located in Africa, Asia, Europe, Oceania and South America. Isolates
were collected from patients with complicated skin and soft-tissue infections and were cultured from
integumentary sources. Methicillin resistance among S. aureus was conﬁrmed locally using the oxacillin
method. The CLSI broth microdilution method was used to measure ceftaroline MICs at the central
laboratory. Versions 7.1 and 8.0 of the EUCAST breakpoints were used to interpret MIC data.
Results: Between 2015 and 2016, 9559 isolates of S. aureus were collected, of which 5566 (58.2%) isolates
were MRSA. Overall, the lowest rate of MRSA was in Asia (56.5%; 705/1247) and the highest rate was in
Oceania (62.7%; 299/477). Using version 7.1 of the EUCAST breakpoints, 4.5% (250/5566) of all MRSA
isolates were resistant to ceftaroline and when version 8.0 of the breakpoints was applied, 4.2%
(235/5566) of MRSAwere in the intermediate category and 0.3% (15/5566) of all isolates were considered
resistant.
Conclusions: By applying version 8.0 of the EUCAST breakpoints, the majority of MRSA isolates that were
resistant are now in the intermediate category for ceftaroline. Ceftaroline resistance among MRSA now
appears rare. E. Urban, Clin Microbiol Infect 2019;25:1429.e1e1429.e4
© 2019 Pﬁzer Inc. and the Authors. Published by Elsevier Ltd. on behalf of European Society of Clinical
Microbiology and Infectious Diseases. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Worldwide, methicillin-resistant Staphylococcus aureus (MRSA)
is frequently isolated from complicated skin and soft-tissue in-
fections (cSSTI) [1,2], and cases of MRSA are increasing among
outpatients [3,4]. Early diagnosis and treatment of cSSTI caused by
MRSA can be linked to lower hospital costs, by reducing treatment
duration and length of stay [5].
Ceftaroline has antimicrobial activity against MRSA and has
been approved for the treatment of cSSTI at a standard dosage of
600 mg every 12 h (given over 60 min) in adults [6]. In 2017, theHealth, Groton Laboratories,
Stone).
ed by Elsevier Ltd. on behalf of Euro
ecommons.org/licenses/by-nc-nd/4European Medicines Agency approved a higher dosing regimen of
ceftaroline (600 mg every 8 h over 120 min) for cSSTI caused by
S. aureus with a ceftaroline MIC of 2 or 4 mg/L.
Having two approved dosing regimens (standard and high) is
one of the criteria that the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) have proposed to use when
assigning an intermediate category for an antimicrobial agent [7].
Hence, an intermediate breakpoint of 2 mg/L was introduced for
ceftaroline against S. aureus, for indications other than pneumonia,
in version 8.0 of the EUCAST breakpoints [8]. As a result, the
EUCAST resistant breakpoint for ceftaroline against S. aureus
increased from>1mg/L in version 7.1 of the breakpoint tables to >2
mg/L in version 8.0 [8,9].
The aim of this study is to present antimicrobial activity data on
ceftaroline against a collection of MRSA isolates from cSSTI, and topean Society of Clinical Microbiology and Infectious Diseases. This is an open access
.0/).
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8.0. Isolates were collected between 2015 and 2016 in Africa, Asia,
Europe, Oceania and South America for the global AWARE (Assess-
ing Worldwide Antimicrobial Resistance Evaluation) surveillance
study (excluding the USA), which now forms part of the ATLAS
(Antimicrobial Testing Leadership and Surveillance) database.
Methods
In this study, 9559 isolates of S. aureus were collected from
patients with cSSTI between 2015 and 2016 for the global AWARE
surveillance study (excluding the USA). Isolates were submitted
from 132 study centers in the following regions: Africa (n ¼ 11),
Asia (n ¼ 18), Europe (n ¼ 72), Oceania (n ¼ 7) and South America
(n ¼ 24). Each center was required to collect 70e95 isolates of
S. aureus. Demographic information recorded for each isolate
included specimen source, and patient age, sex and location in the
hospital. To be included in the study, isolates had to be considered
the likely causative pathogen of infection and, to be included in this
analysis, must have been cultured from integumentary specimens,
such as abscesses, burns, impetiginous lesions or wounds. Isolates
were excluded if they came from in situ drains or drainage bottles,
were environmental samples or were duplicate isolates (the same
species from the same or different body site isolated at the same
time or at any subsequent time from the same patient).
All isolates were identiﬁed locally and shipped to the central
laboratory (International Health Management Associates, Inc.,
Schaumburg, IL, USA) for susceptibility testing. The methicillin-
resistance status of each S. aureus isolate was determined using
the oxacillin method (an oxacillin MIC of 4 mg/L conﬁrmed
methicillin resistance), in accordance with the CLSI deﬁnitions [10].
Ceftaroline MICs were determined using broth microdilution
methodology according to CLSI guidelines [11]. The testing range
for ceftaroline was 0.015e32 mg/L. Ceftaroline MIC values were
interpreted using versions 7.1 (susceptible, 1 mg/L and resistant,
>1 mg/L) and 8.0 (susceptible, 1 mg/L; intermediate, 2 mg/L and
resistant, >2 mg/L) of the EUCAST breakpoints for indications other
than pneumonia [8,9].
Results
In this study, a total of 5566 (58.2%) isolates of MRSA were
identiﬁed from 9559 isolates of S. aureus. The majority of MRSA
isolates were collected from inpatients (82.0%; 4562/5566), 58.0%
(3227/5566) of isolates were collected from male patients, and
52.4% (2916/5566) of isolates were from patients aged between 18
and 64 years. Most isolates were collected from wounds (52.8%;
2940/5566) and abscesses (23.0%; 1282/5566). The remaining
isolates were collected from burns, carbuncles, cellulitis/erysipelas,
decubitus, furuncles, impetiginous lesions, skin, skin ulcers or other
sources.
The rates of MRSA, by region and year, are presented in Table 1.
The overall rate of MRSA collected in all regions over the studyTable 1
Rates of MRSA collected from patients with cSSTI (2015e2016)
Region 2015 n (%) 2016 n (%) 2015e2016 n (%)
Africa 298 (61.4) 284 (58.7) 582 (60.1)
Asia 375 (56.4) 330 (56.7) 705 (56.5)
Europe 1436 (60.0) 1492 (56.9) 2928 (58.4)
Oceania 127 (65.1) 172 (61.0) 299 (62.7)
South America 621 (57.8) 431 (55.7) 1052 (56.9)
All regions 2857 (59.3) 2709 (57.1) 5566 (58.2)
Abbreviations: cSSTI, complicated skin and soft-tissue infections; MRSA,
methicillin-resistant Staphylococcus aureus.period was 58.2% (5566/9559). By region, the lowest rate of MRSA
was in Asia (56.5%; 705/1247) and the highest rate was in Oceania
(62.7%; 299/477). By year, in each region except Asia, there was a
small decrease in rates of MRSA between 2015 and 2016. In Asia, the
rates of MRSA in 2015 and 2016 were similar (56.4%; 375/665, and
56.7%; 330/582, respectively).
The in vitro antimicrobial activity of ceftaroline against MRSA
isolates collected in this study is presented in Table 2. The overall
ceftaroline MIC50 and MIC90 values in all regions over the study
period were 0.5 and 1 mg/L, respectively, and the same MIC50 and
MIC90 values were observed over the study period in each region.
By year, the ceftaroline MIC50 was also 0.5 mg/L in each region, and
theMIC90 was 1mg/L in all years except 2015 in Asia (MIC90 2mg/L)
and 2016 in Oceania (MIC90 0.5 mg/L).
According to version 7.1 of the EUCAST breakpoints, the overall
percentage of MRSA isolates that were resistant to ceftaroline in all
regions over the study period was 4.5% (250/5566; Table 2). When
version 8.0 of the breakpoints was applied, 0.3% (15/5566) of all
isolates collected were in the resistant category and 4.2% (235/
5566) were in the intermediate category. By region, when version
7.1 of the EUCAST breakpoints was used, the rates of ceftaroline
resistance ranged from 1.0% (3/299; Oceania) to 7.8% (55/705; Asia).
Applying version 8.0 of the breakpoints for each region, Oceania
had both the lowest rate of ceftaroline-resistant MRSA isolates and
the lowest rate of ceftaroline-intermediate isolates (0.0%; 0/299,
and 1.0%; 3/299, respectively). The highest rate of ceftaroline-
resistant MRSA was collected in Asia (1.8%; 13/705), and the high-
est rate of ceftaroline-intermediate isolates was collected in South
America (7.5%; 79/1052).
Applying version 7.1 of the EUCAST breakpoints, there was a
decrease in ceftaroline resistance between 2015 and 2016 in each
region except South America, where rates were 7.1% (44/621) and
8.4% (36/431), respectively (Table 2). Using the version 8.0 break-
points, there were similar rates of ceftaroline resistance among
MRSA in each region in 2015 and 2016 (0.0%e0.2%) except in Asia,
where ceftaroline resistance decreased from 2.9% (11/375) in 2015
to 0.6% (2/330) in 2016. Between study years, there was a decrease
in the proportion of ceftaroline-intermediate MRSA isolates
between 2015 and 2016 in all regions except South America.
Discussion
The focus of this study was the revision of the EUCAST break-
points for ceftaroline against S. aureus and the effects on the sus-
ceptibility to ceftaroline among a collection of MRSA isolates from
cSSTI. In version 8.0 of the EUCAST breakpoints, an intermediate
category was introduced for ceftaroline against S. aureus, for in-
dications other than pneumonia, and the resistant breakpoint
increased to >2 mg/L [8,9].
Applying version 7.1 of the EUCAST breakpoints for ceftaroline
and S. aureus, the overall rate of ceftaroline resistance amongMRSA
isolates in the current study was 4.5%. With version 8.0 of the
breakpoints, previously resistant isolates according to version 7.1
became largely assigned to the intermediate category for ceftaro-
line, and the overall rate of ceftaroline resistance decreased to 0.3%.
By region, with version 8.0, rates of ceftaroline-resistant MRSA
decreased to 0.0%e0.1% in Africa, Europe, Oceania and South
America, and decreased to 1.8% in Asia. This change reﬂects a low
occurrence ofMRSA isolates from cSSTI with a ceftarolineMIC value
of > 2 mg/L in the regions presented here.
Ceftaroline can therefore be considered a treatment option for
cSSTI caused byMRSA, provided that steps are taken to quantify the
in vitro susceptibility of MRSA to ceftaroline to ensure that the
correct dosing regimen is administered. Although S. aureus isolates
with ceftaroline MICs of 4 mg/L are rare [12,13], there is evidence to
Table 2
In vitro activity of ceftaroline against a collection of MRSA isolates from patients with cSSTI (2015e2016)
Region, year Isolates (n) MIC (mg/L) EUCAST version 7.1a (%) EUCAST version 8.0b (%)
MIC50 MIC90 Range S I R S I R
Africa
2015 298 0.5 1 0.25e2 94.0 d 6.0 94.0 6.0 0.0
2016 284 0.5 1 0.25e2 98.6 d 1.4 98.6 1.4 0.0
2015e2016 582 0.5 1 0.25e2 96.2 d 3.8 96.2 3.8 0.0
Asia
2015 375 0.5 2 0.12e4 89.3 d 10.7 89.3 7.7 2.9
2016 330 0.5 1 0.12e4 95.5 d 4.5 95.5 3.9 0.6
2015e2016 705 0.5 1 0.12e4 92.2 d 7.8 92.2 6.0 1.8
Europe
2015 1436 0.5 1 0.03e4 96.8 d 3.2 96.8 3.1 0.1
2016 1492 0.5 1 0.06e2 97.1 d 2.9 97.1 2.9 0.0
2015e2016 2928 0.5 1 0.03e4 96.9 d 3.1 96.9 3.0 <0.05
Oceania
2015 127 0.5 1 0.25e2 97.6 d 2.4 97.6 2.4 0.0
2016 172 0.5 0.5 0.25e1 100 d 0.0 100 0.0 0.0
2015e2016 299 0.5 1 0.25e2 99.0 d 1.0 99.0 1.0 0.0
South America
2015 621 0.5 1 0.25e4 92.9 d 7.1 92.9 6.9 0.2
2016 431 0.5 1 0.12e2 91.6 d 8.4 91.6 8.4 0.0
2015e2016 1052 0.5 1 0.12e4 92.4 d 7.6 92.4 7.5 0.1
All regions
2015 2857 0.5 1 0.03e4 94.7 d 5.3 94.7 4.8 0.5
2016 2709 0.5 1 0.06e4 96.3 d 3.7 96.3 3.6 0.1
2015e2016 5566 0.5 1 0.03e4 95.5 d 4.5 95.5 4.2 0.3
Abbreviations: cSSTI, complicated skin and soft-tissue infections; MIC, minimum inhibitory concentration; MIC50, MIC required to inhibit growth of 50% of isolates (mg/L);
MIC90, MIC required to inhibit growth of 90% of isolates (mg/L); MRSA, methicillin-resistant Staphylococcus aureus; I, intermediate; R, resistant; S, susceptible.
–, no breakpoints available.
a EUCAST breakpoints version 7.1: S, 1 mg/L and R, >1 mg/L [9].
b EUCAST breakpoints version 8.0: S, 1 mg/L and R, >2 mg/L [8].
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effective treatment option [14]. Using a population pharmacoki-
netic model comprising pharmacokinetic data from 21 clinical
studies, a high probability of target attainment (>90%) was pre-
dicted for ceftaroline at 600 mg every 8 h against S. aureus with
ceftaroline MICs of 4 mg/L [14].
The revised ceftaroline resistance rate against MRSA reported by
this study in Asia (1.8%), using version 8.0 of the EUCAST break-
points, was higher than in other participating regions. Previous
studies have identiﬁed a set of MRSA isolates collected in Thailand
with ceftaroline MIC values of 2 mg/L [12,13,15]. Among the iso-
lates selected for molecular characterization, the majority with
ceftaroline MIC values of 2 mg/L had a single amino acid substi-
tution in the non-penicillin-binding domain of penicillin-binding
protein 2a (PBP2a), and isolates with ceftaroline MICs of 4 mg/L
[13] or 8 mg/L [12,15] all had an additional single amino acid sub-
stitution in the penicillin-binding domain of PBP2a.
The data presented in this study show that the rates of MRSA
from patients with cSSTI were >50% in each region submitting
isolates, and that the rates did not vary greatly from the overall rate
of 58.2% for the study period. This reafﬁrms that MRSA is a common
cause of cSSTI globally, and that recent rates seem to be consistent,
year-on-year. In surveillance studies of isolates from skin infections,
high rates of MRSA have also been reported: Africa and the Middle
East, 53.6% (883/1646) in 2012e2014 [16]; Asia-Paciﬁc and South
Africa, 31.8% in 2011 [17]; Europe, Russia and Turkey, 56.8%
(1467/2583) in 2012 [18]; and Latin America, 56.0% (390/696) in
2012 [19]. The lower rates of MRSA reported by Flamm et al. [17]
may indicate that MRSA rates have increased in certain regions
since 2011; however, rates of MRSA are also inﬂuenced by their
contributing study centers and countries, which are likely to differ
between studies.
Reported rates of MRSAmay also depend upon specimen source.
The yearly rates of MRSA presented in this study (59.3% in 2015 and
57.1% in 2016), were for integumentary sources from patients withcSSTI. The European Centre for Disease Prevention and Control
(ECDC) published notably lower MRSA rates (population-weighted
means across 30 European countries) of 16.9% in 2015 and 13.7% in
2016 [4], solely from invasive isolates (blood and cerebrospinal
ﬂuid). In their report, they note that invasive isolates may not be
representative of isolates of the same bacterial species from other
type of infections, and list wound infections as an example. In the
present study, the majority of isolates were collected fromwounds
(52.8%).
In line with the ceftaroline breakpoint revisions by EUCAST
based on the higher dosing regimen approved by the European
Medicines Agency, the CLSI revised their ceftaroline MIC break-
points in January 2019. The intermediate and resistant CLSI
breakpoints for ceftaroline of 2 and 4 mg/L, respectively, have
been replaced by a new susceptible-dose-dependent MIC category
of 2e4 mg/L and an increased resistant breakpoint of 8 mg/L [20].
There are a number of limitations associated with the collection
of isolates for surveillance studies such as AWARE that should be
borne in mind when considering these results. First, participating
study centers are not located in every country of each region, and
some regions have more participating centers than others
(e.g. 52.6% of all MRSA isolates collected in the current study were
obtained from Europe). Therefore, all countries or regions are not
equally represented. Second, years of participation can vary for the
same center, whichmay not collect isolates year-on-year. Also, each
study center is required to collect a deﬁned number of isolates for
each bacterial species (limited to one isolate per species per pa-
tient) from a limited number of infection types. Furthermore, this
study did not include isolates collected in the USA. Therefore, the
data presented here are representative of a collection of isolates,
rather than showing the true prevalence of ceftaroline resistance
among MRSA isolates from around the world.
Despite these limitations this is the ﬁrst surveillance study, to
date, showing the impact of revised EUCAST breakpoints for cef-
taroline on the ceftaroline susceptibility of MRSA isolates from
E. Urban, G.G. Stone / Clinical Microbiology and Infection 25 (2019) 1429.e1e1429.e41429.e4cSSTI. The ﬁndings indicate that for the regions included in this
study, MRSA isolates with a ceftaroline MIC value of > 2 mg/L are
rare, and most isolates that were previously considered resistant to
ceftaroline can now be categorized as intermediate.
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